Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers

Myriam Arévalo-Herrera, David A Forero-Peña, Kelly Rubiano, José Gómez-Hincapie, Nora L Martínez, Mary Lopez-Perez, Angélica Castellanos, Nora Céspedes, Ricardo Palacios, José Millán Oñate, Sócrates Herrera, Myriam Arévalo-Herrera, David A Forero-Peña, Kelly Rubiano, José Gómez-Hincapie, Nora L Martínez, Mary Lopez-Perez, Angélica Castellanos, Nora Céspedes, Ricardo Palacios, José Millán Oñate, Sócrates Herrera

Abstract

Background: Significant progress has been recently achieved in the development of Plasmodium vivax challenge infections in humans, which are essential for vaccine and drug testing. With the goal of accelerating clinical development of malaria vaccines, the outcome of infections experimentally induced in naïve and semi-immune volunteers by infected mosquito bites was compared.

Methods: Seven malaria-naïve and nine semi-immune Colombian adults (n = 16) were subjected to the bites of 2-4 P. vivax sporozoite-infected Anopheles mosquitoes. Parasitemia levels, malaria clinical manifestations, and immune responses were assessed and compared.

Results: All volunteers developed infections as confirmed by microscopy and RT-qPCR. No significant difference in the pre-patent period (mean 12.5 and 12.8 days for malaria-naïve and malaria-exposed, respectively) was observed but naïve volunteers developed classical malaria signs and symptoms, while semi-immune volunteers displayed minor or no symptoms at the day of diagnosis. A malaria-naïve volunteer developed a transient low submicroscopic parasitemia that cured spontaneously. Infection induced an increase in specific antibody levels in both groups.

Conclusion: Sporozoite infectious challenge was safe and reproducible in semi-immune and naïve volunteers. This model will provide information for simultaneous comparison of the protective efficacy of P. vivax vaccines in naïve and semi-immune volunteers under controlled conditions and would accelerate P. vivax vaccine development.

Trial registration: clinicaltrials.gov NCT01585077.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow chart of study design…
Figure 1. Flow chart of study design and volunteers recruitment.
Figure 2. Course of parasitemia determined by…
Figure 2. Course of parasitemia determined by RT-qPCR.
Parasitemia determined between days 0 and 16 of post-challenge follow-up. Each point represents parasites/µL (Log10) in (A) naïve (n = 6) and (B) semi-immune (n = 9) volunteers. Solid lines represent pretreatment and dashed lines post-treatment.
Figure 3. Specific antibody responses against P.…
Figure 3. Specific antibody responses against P. vivax antigens in naïve and semi-immune volunteers.
Antibodies are expressed as reactivity index defined as OD values of tested sample divided by the cut-off value. Reactivity indexes against (A) PvsCs and (B) PvMSP-1 in naïve volunteers (n = 7). Reactivity indexes against (C) PvsCS and (D) PvMSP-1 in semi-immune volunteers (n = 9).

References

    1. Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, et al. (2005) Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25–31.
    1. Arevalo-Herrera M, Quinones ML, Guerra C, Cespedes N, Giron S, et al. (2012) Malaria in selected non-Amazonian countries of Latin America. Acta Trop 121: 303–314.
    1. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, et al. (2005) Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23: 3131–3138.
    1. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, et al. (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3: e2636.
    1. Bell BA, Wood JF, Bansal R, Ragab H, Cargo J 3rd, et al. (2009) Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax . Vaccine 27: 1448–1453.
    1. Chitnis CE, Sharma A (2008) Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24: 29–34.
    1. Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, et al. (2008) Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. Vaccine 26: 4338–4344.
    1. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, et al. (2005) Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73: 16–24.
    1. Molina DM, Finney OC, Arevalo-Herrera M, Herrera S, Felgner PL, et al. (2012) Plasmodium vivax pre-erythrocytic-stage antigen discovery: exploiting naturally acquired humoral responses. Am J Trop Med Hyg 87: 460–469.
    1. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, et al. (2005) Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73: 3–9.
    1. Herrera S, Fernandez OL, Vera O, Cardenas W, Ramirez O, et al. (2011) Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 84: 12–20.
    1. Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, et al. (2012) Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 30: 3311–3319.
    1. Laurens MB, Duncan CJ, Epstein JE, Hill AV, Komisar JL, et al. (2012) A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 30: 5302–5304.
    1. WHO (1997) Guidelines for the Evaluation of Plasmodium falciparum Asexual Blood-Stage Vaccines in Populations Exposed to Natural Infection. World Health Organization, Geneva.
    1. Genton B, D'Acremont V, Lurati-Ruiz F, Verhage D, Audran R, et al. (2010) Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum . Vaccine 28: 6573–6580.
    1. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, et al. (2010) Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490.
    1. Stoute JA (2012) Malaria sporozoite challenge model comes of age. Pathog Glob Health 106: 320.
    1. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, et al. (2013) The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8: e61395.
    1. McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, et al. (2013) Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy Volunteers. J Infect Dis 208: 1688–1694.
    1. Noulin F, Borlon C, Van Den Abbeele J, D'Alessandro U, Erhart A (2013) 1912-2012: a century of research on Plasmodium vivax in vitro culture. Trends Parasitol 29: 286–294.
    1. Herrera S, Fernandez O, Manzano MR, Murrain B, Vergara J, et al. (2009) Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg 81: 740–746.
    1. Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, et al. (2011) Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg 84: 4–11.
    1. International Conference on Harmonisation (1996) ICH Harmonised Tripartite Guideline — Guideline for Good Clinical Practice E6 (R1).
    1. Sousa TN, Sanchez BA, Ceravolo IP, Carvalho LH, Brito CF (2007) Real-time multiplex allele-specific polymerase chain reaction for genotyping of the Duffy antigen, the Plasmodium vivax invasion receptor. Vox Sang 92: 373–380.
    1. Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, et al. (1997) Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus . Ann Trop Med Parasitol 91: 49–60.
    1. Herrera S, Vallejo AF, Quintero JP, Arevalo-Herrera M, Cancino M, et al. (2014) Field evaluation of an automated RDT reader and data management device for Plasmodium falciparum/Plasmodium vivax malaria in endemic areas of Colombia. Malar J 13: 87.
    1. Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, et al. (2004) Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J Clin Microbiol 42: 5636–5643.
    1. Solarte Y, Manzano MR, Rocha L, Hurtado H, James MA, et al. (2011) Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials. Am J Trop Med Hyg 84: 28–34.
    1. Shute PG, Maryon M (1963) An Improved Technique for Staining Malaria Parasites with Giemsa Stain. Arch Roum Pathol Exp Microbiol 22: 887–894.
    1. MinSalud (2010) Guía para atención clínica integral del paciente con malaria. Bogotá: Ministerio de la Protección Social.
    1. FDA (2007) Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. In: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, editors.
    1. Arevalo-Herrera M, Solarte Y, Rocha L, Alvarez D, Beier JC, et al. (2011) Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast. Am J Trop Med Hyg 84: 71–77.
    1. Arevalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, et al. (1998) Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539–551.
    1. Cespedes N, Arevalo-Herrera M, Felger I, Reed S, Kajava AV, et al. (2013) Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein. Vaccine 31: 4923–4930.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377–381.
    1. SIVIGILA (2012) Sistema Nacional de Vigilancia en Salud Pública.: Instituto Nacional de Salud.
    1. Chaparro P, Padilla J, Vallejo AF, Herrera S (2013) Characterization of a malaria outbreak in Colombia in 2010. Malar J 12: 330.
    1. Rodriguez JC, Uribe GA, Araujo RM, Narvaez PC, Valencia SH (2011) Epidemiology and control of malaria in Colombia. Mem Inst Oswaldo Cruz 106 Suppl 1114–122.
    1. Beier JC, Onyango FK, Ramadhan M, Koros JK, Asiago CM, et al. (1991) Quantitation of malaria sporozoites in the salivary glands of wild Afrotropical Anopheles. Med Vet Entomol 5: 63–70.
    1. Grieco JP, Achee NL, Roberts DR, Andre RG (2005) Comparative susceptibility of three species of Anopheles from Belize, Central America, to Plasmodium falciparum (NF-54). J Am Mosq Control Assoc 21: 279–290.
    1. Artavanis-Tsakonas K, Tongren JE, Riley EM (2003) The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 133: 145–152.
    1. Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonchai A, et al. (2004) Hematologic and clinical indices of malaria in a semi-immune population of western Thailand. Am J Trop Med Hyg 70: 8–14.
    1. Zimmerman PA, Ferreira MU, Howes RE, Mercereau-Puijalon O (2013) Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv Parasitol 81: 27–76.
    1. Imwong M, Nair S, Pukrittayakamee S, Sudimack D, Williams JT, et al. (2007) Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol 37: 1013–1022.
    1. Karunaweera ND, Ferreira MU, Munasinghe A, Barnwell JW, Collins WE, et al. (2008) Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax . Gene 410: 105–112.
    1. Russell B, Suwanarusk R, Lek-Uthai U (2006) Plasmodium vivax genetic diversity: microsatellite length matters. Trends Parasitol 22: 399–401.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren